Institutions / ADAR1 Capital Management, LLC
ADAR1 Capital Management, LLC
CIK 1940272 · Institution · as of Dec 31, 2025
Portfolio value
$1.34B
Positions
249
As of
Dec 31, 2025
Top holdings
Dec 31, 2025View all 249 →
| Company | Value | % of portfolio |
|---|---|---|
| Abivax SA | $177.65M | 13.3% |
| Protagonist Therapeutics Inc | $91.63M | 6.9% |
| Roivant Sciences Ltd. | $74.41M | 5.6% |
| Immunovant, Inc.IMVT | $63.07M | 4.7% |
| Avidity Biosciences, Inc. | $39.42M | 2.9% |
| Ea Series Trust | $38.80M | 2.9% |
| SPDR S&P 500 ETF Tr | $37.29M | 2.8% |
| Cytokinetics Inc | $34.32M | 2.6% |
| Septerna, Inc.SEPN | $32.27M | 2.4% |
| Arbutus Biopharma CorpABUS | $26.05M | 1.9% |
| Zai Lab Limited | $21.99M | 1.6% |
| Terns Pharmaceuticals, Inc. | $21.88M | 1.6% |
| CytomX Therapeutics, Inc. | $17.82M | 1.3% |
| Celldex Therapeutics, Inc. | $17.57M | 1.3% |
| Rapt Therapeutics Inc | $17.26M | 1.3% |
| Inhibikase Therapeutics, Inc. | $16.53M | 1.2% |
| BridgeBio Pharma, Inc. | $16.32M | 1.2% |
| Monopar Therapeutics Inc.MNPR | $15.27M | 1.1% |
| Vaxcyte, Inc. | $14.56M | 1.1% |
| Crinetics Pharmaceuticals, Inc. | $14.40M | 1.1% |
| Fulcrum Therapeutics, Inc. | $14.18M | 1.1% |
| Prothena Corp Public Ltd Co | $13.92M | 1.0% |
| Lexeo Therapeutics, Inc. | $13.83M | 1.0% |
| Taysha Gene Therapies, Inc.TSHA | $13.73M | 1.0% |
| Cidara Therapeutics Inc | $13.18M | 1.0% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.